Skip to content

Fomentation therapy in management of multiple joint pain

An open labelled randomized comparative clinical study to evaluate the efficacy of sarvanga lavana pottali sweda and sarvanga aavikizhi with nitya virechana in Amavata vis-a-vis Rheumatoid Arthritis - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087424
Enrollment
40
Registered
2025-05-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M069- Rheumatoid arthritis, unspecified

Interventions

None listed

Sponsors

Dr Aishwarya P
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects who fulfill diagnostic criteria of Rheumatoid arthritis/Amavata irrespective of gender, religion, occupation and age group between 18-60 years will be included. 2.Subjects with or without on DMARD medications will be included. 3.Subjects fit for Swedana. 4.Subjects fit for Nitya virechana. 5.Both sero positive and sero negative subjects of RA .

Exclusion criteria

Exclusion criteria: 1.Subjects with other systemic diseases like uncontrolled Diabetes mellitus, uncontrolled hypertension, which would interfere the present study. 2.Subjects of other connective tissue disorders like SLE, polymyositis, scleroderma etc, other than RA. 3.Subjects who have developed extra-articular complications of RA like pleural effusions, myocarditis, vasculitis etc. 4.Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Reduction in pain, swelling, stiffness of the joints involvedTimepoint: 0th day and 7th day

Secondary

MeasureTime frame
Reduction in joint tendernessTimepoint: 8 days

Countries

India

Contacts

Public ContactDr Veena G Rao

JSS Ayurveda medical college and hospital

drveenagrao@yahoo.in9844549152

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026